3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Melanoma
1
Interventions
Cyclophosphamide
3
fludarabine
2
Paclitaxel
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
olaparib
1
niraparib
1
mirvetuximab soravtansine
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
Tinzaparin
1
Propranolol
1
Palliative Care
1
Nivolumab
1
Neoadjuvant Therapy
1
Music Therapy
1
Losartan
1
Indocyanine Green
1
GEN-1
1
Etodolac
1
E7777 fusion protein
1
Clarithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled